Clinical Trial Detail

NCT ID NCT01928576
Title Phase II Anti-PD1 Epigenetic Priming Study in NSCLC.
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Sidney Kimmel Comprehensive Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Nivolumab

Entinostat

Azacitidine

Age Groups: adult

No variant requirements are available.